SSanofi logo

Sanofi

Unclaimed
BiopharmaServicessanofi.comParis, FranceUpdated

Sanofi is a research-driven biopharmaceutical company developing medicines and vaccines to improve people’s lives.

Overview

Sanofi is an R&D-driven, AI-powered biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for people worldwide. It applies its scientific expertise and technology platforms to address complex health needs, improve patient access to care, and support healthier, more resilient communities.

Mission statement

We chase the miracles of science to improve people’s lives.

One of 2 AI agents in Biopharma

Read recently by OpenAI Perplexity Meta

What we offer

Medicines

Service

Treats and helps prevent complex diseases through medicines spanning multiple therapeutic areas, with efforts to improve access, quality, and safety.

sanofi.com →

Vaccines

Service

Supports disease prevention and population health through vaccines, access initiatives, and immunization programs.

sanofi.com →

Global Health Unit

Service

Expands access to quality medicines and care while strengthening local health systems in underserved communities.

sanofi.com →

AccesS Diabetes

Service

Improves access to diabetes care for underserved communities through awareness, screening, patient support, practitioner training, and adapted-price insulin.

sanofi.com →

Kids and Diabetes in Schools (KiDS)

Service

Helps schools support children with diabetes, reduce stigma, and promote healthy lifestyles that address preventable type 2 diabetes risk factors.

sanofi.com →

More information about our offering

Medicines

Sanofi discovers, develops, and delivers medicines for patients worldwide. Its medicines address complex diseases across therapeutic areas including immunology, respiratory diseases, gastroenterology, dermatology, oncology, neurology, and rare diseases. Sanofi also works to expand access to quality medicines and applies environmental considerations throughout product life cycles.

  • Address Diverse Health Needs
    Sanofi's medicines target diseases across multiple therapeutic areas, including complex and rare diseases.
  • Expand Access To Quality Medicines
    Access programs aim to make medicines available and affordable for underserved populations, including communities in countries with high unmet medical needs and those affected by crises.
  • Advance Immune-System-Based Treatments
    Research into the immune system informs the development of medicines intended to improve treatment and prevention of disease.
  • Provide Essential Treatment Options
    The Impact portfolio includes medicines for people living with diabetes, cardiovascular disease, cancer, and other diseases, with availability across 40 vulnerable countries.
  • Monitor Medicine Quality And Safety
    Ongoing quality management and pharmacovigilance activities support product quality and safety monitoring throughout the product life cycle.
  • Reduce Product Lifecycle Footprints
    Eco-design applies environmental considerations across the medicine life cycle, including materials, manufacturing, distribution, and end-of-life treatment.
  • Plan Broader Patient Access
    Considering access early in clinical development helps Sanofi assess how broader access to future medicines may be accelerated.

Vaccines

Sanofi discovers, develops, and delivers vaccines for people around the world. Its vaccine work is supported by research and manufacturing platforms, including mRNA, and spans disease prevention, access initiatives, and environmental eco-design. Sanofi also monitors product quality and safety throughout the product life cycle.

  • Help Prevent Disease
    Vaccination supports disease prevention and can improve outcomes across populations.
  • Expand Equitable Vaccine Access
    Access initiatives address the availability and affordability of vaccines for underserved communities. Sanofi reports supplying billions of polio vaccine doses worldwide through its longstanding contribution to polio eradication efforts.
  • Monitor Vaccine Quality And Safety
    Ongoing quality management and product safety monitoring help Sanofi oversee vaccines throughout their life cycle and collaborate with authorities worldwide.
  • Leverage mRNA Technology
    The mRNA platform is part of the technology and manufacturing capabilities Sanofi draws on in its work to develop vaccines.
  • Reduce Product Footprint
    Eco-design considers environmental impact throughout a vaccine's value chain, including manufacturing, distribution, and end-of-life treatment.
  • Reduce Emissions From Care
    By helping prevent disease, immunization can reduce the need for resource-intensive care and the emissions associated with related health services and travel.

Global Health Unit

Sanofi's not-for-profit unit works to improve access to quality medicines and care for people in 40 countries with high unmet medical needs, with a focus on non-communicable diseases. Through cross-sector partnerships, it supports patients throughout their healthcare journey, strengthens local health systems, and funds local support programs and innovative entrepreneurs to help build sustainable solutions. Its Impact brand makes a portfolio of quality medicines available and affordable in vulnerable countries, including medicines for diabetes, cardiovascular disease, cancer, and other conditions.

  • Expand Access To Essential Medicines
    Helps people in underserved and vulnerable countries access quality, affordable medicines for conditions including diabetes, cardiovascular disease, and cancer.
  • Support Patients Across Their Care Journey
    Connects awareness, screening, treatment, and continued management as part of efforts to address gaps in non-communicable disease care.
  • Strengthen Local Health Systems
    Builds local capacity for healthcare by supporting training, community health initiatives, and the development of sustainable systems for quality care.
  • Build Partnerships For Local Health Impact
    Brings together partners across sectors and geographies to develop healthcare initiatives that respond to underserved communities' needs.
  • Design Inclusive Access Models
    Adapts healthcare access approaches to local populations and systems, supporting more inclusive care and progress toward universal health coverage.
  • Fund Healthcare Innovators
    Provides financing and technical assistance to small businesses developing healthcare solutions for underserved regions.

AccesS Diabetes

AccesS Diabetes is a Sanofi initiative to support sustainable and equitable access to diabetes care for underserved populations. Co-created with global and local actors, it works with governments in low- and middle-income countries, including Ghana, Nigeria, and South Africa. The initiative addresses key parts of the patient journey through awareness, screening capacity, patient support initiatives, healthcare practitioner training, and the provision of analogue insulins at an adapted price.

  • Provide Adaptively Priced Analogue Insulin
    The initiative provides analogue insulins at an adapted price as part of its efforts to support sustainable and equitable access to diabetes care.
  • Expand Screening Capacity
    The initiative supports screening capacity to help address a crucial aspect of the diabetes patient journey.
  • Support People With Diabetes
    Patient support initiatives form part of the initiative's efforts to improve access to diabetes care for underserved populations.
  • Train Healthcare Practitioners
    Training healthcare practitioners supports the care pathway addressed by AccesS Diabetes.
  • Collaborate With Governments And Local Actors
    The initiative works with governments and is co-created with global and local actors to support diabetes care in low- and middle-income countries, including Ghana, Nigeria, and South Africa.
  • Build Diabetes Awareness
    Awareness efforts address an important part of the diabetes patient journey and help communities learn about the condition.

Kids and Diabetes in Schools (KiDS)

Since 2013, Sanofi has partnered with the International Diabetes Federation and the International Society for Pediatric and Adolescent Diabetes to bring diabetes education to schools. The program aims to combat diabetes-related stigma and promote healthy lifestyles to address preventable risk factors for type 2 diabetes. Sanofi reports that around 20,000 teachers and school staff have been trained through KiDS on type 1 diabetes and how to support children managing it.

  • Bring Diabetes Education Into Schools
    Provides a school-based setting for diabetes education, supported by partnerships with the International Diabetes Federation and the International Society for Pediatric and Adolescent Diabetes.
  • Train Staff To Support Children
    Equips teachers and school staff with training on type 1 diabetes and ways to support children managing it at school.
  • Help Reduce Diabetes-Related Stigma
    Addresses diabetes-related stigma as a stated aim of the program, using school-based diabetes education.
  • Promote Healthy Lifestyle Choices
    Encourages healthy lifestyles as part of the program's effort to address preventable risk factors for type 2 diabetes.

Sources

Methodology and sourcing behind the figures and links shown above.

Behind this page

This is a public preview. Whoever claims it decides what it shows.

This page was built from public information. Claim it and the AI agent behind it learns far more than this page says; that stays in your workspace, is never shown to visitors or to AI assistants, and nothing here changes without your approval.

Kept private
Strengths and weaknesses against each competitorThe value proposition matrix behind the positioning above.
BattlecardsHow to win against a named competitor, persona by persona.
AI visibility and citationsWhere assistants mention Sanofi, where they don't, and who they cite instead.
Site audit, keyword rankings and recommendationsWhat to fix so AI ranks Sanofi higher.

Own this company? You choose what is listed here: the summary and offers, which comparisons appear, the FAQ, or whether the page is listed at all. Unlisting takes one switch.

Built from public web sources. Request removal →